Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAge Labs (BIOA) Other Accumulated Expenses (2023 - 2026)

BioAge Labs' Other Accumulated Expenses history spans 3 years, with the latest figure at $525000.0 for Q4 2025.

  • On a quarterly basis, Other Accumulated Expenses rose 25.9% to $525000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $525000.0, a 25.9% increase, with the full-year FY2025 number at $525000.0, up 25.9% from a year prior.
  • Other Accumulated Expenses hit $525000.0 in Q4 2025 for BioAge Labs, down from $890000.0 in the prior quarter.
  • Over the last five years, Other Accumulated Expenses for BIOA hit a ceiling of $1.7 million in Q3 2024 and a floor of $417000.0 in Q4 2024.
  • Historically, Other Accumulated Expenses has averaged $918000.0 across 3 years, with a median of $890000.0 in 2025.
  • Biggest five-year swings in Other Accumulated Expenses: plummeted 69.98% in 2024 and later increased 25.9% in 2025.
  • Tracing BIOA's Other Accumulated Expenses over 3 years: stood at $1.4 million in 2023, then plummeted by 69.98% to $417000.0 in 2024, then rose by 25.9% to $525000.0 in 2025.
  • Business Quant data shows Other Accumulated Expenses for BIOA at $525000.0 in Q4 2025, $890000.0 in Q3 2025, and $911000.0 in Q2 2025.